US EditionZepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
- On May 11, 2025, Eli Lilly reported that in the 72-week SURMOUNT-5 trial involving 751 U.S. participants who were obese or overweight with related health conditions but did not have diabetes, Zepbound achieved greater weight loss compared to Wegovy.
- The trial aimed to show Zepbound's superiority over Wegovy by measuring percent weight change, comparing tirzepatide, which targets GLP-1 and GIP receptors, to semaglutide, which targets GLP-1 alone.
- Participants treated with Zepbound experienced an average weight loss of 20.2%, surpassing the 13.7% reduction achieved by those on Wegovy, while waist circumference decreased by 18.4 cm with Zepbound compared to 13.0 cm with Wegovy.
- Louis J. Aronne, principal investigator, noted that tirzepatide achieved more significant weight loss than semaglutide in the SURMOUNT-5 trial, reinforcing its potential as a valuable treatment for managing obesity.
- Both drugs caused mostly mild to moderate gastrointestinal side effects, with 6.1% discontinuing Zepbound and 8.0% discontinuing Wegovy due to adverse events, suggesting Zepbound offers a more effective obesity treatment with manageable safety profiles.
220 Articles
220 Articles
Zepbound or Wegovy? Head-to-Head Trial Says One Is Better for Weight Loss
People who took Zepbound had greater reductions in waist circumference and body weight, a study found.Fact checked by Nick BlackmerMunro / Getty ImagesIn a head-to-head trial, Zepbound beat out Wegovy for weight loss, a clinical trial showed.Experts say that both drugs are safe and effective options for treating obesity.Though Zepbound led to greater weight loss, factors such as insurance coverage and secondary treatment indications can impact w…
PODCAST: CFRA's House Calls for Sun. May 11th, 2025
Eli Lilly has plastered a 'fat tax' on the Canadian market for their weight loss drug. Dr. Yoni Freedhoff joins the program with his reaction. Then, Dr. Dworkin opens the phone lines and reads your texts.
This GLP-1 Is the Most Effective for Weight Loss, Study Says
A new study says that people who use tirzepatide lose more weight than people who use semaglutide Getty Stock image of a woman weighing herself.Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications The study was funded by Eli Lilly, the pharmaceutical company that manufactures tirzepatide, so "take that with a grain of salt," one expert saidTirzepatide, which reduces appetite and improves h…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
